New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 10, 2014
13:50 EDTALIM, CBMX, BIOS, VICL, IPCIVical, CombiMatrix poised for breakouts, says
In a report on stocks with technical attributes that indicate they may be poised for a near-term breakout, TheStreet's Roberto Pedone identifies CombiMatrix (CBMX), Vical (VICL), Intellipharmaceutics (IPCI), BioScrip (BIOS) and Alimera Sciences (ALIM). Reference Link
News For VICL;CBMX;IPCI;BIOS;ALIM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 25, 2015
06:05 EDTCBMXCombiMatrix expands sales team
CombiMatrix has hired seven sales representatives since June 1 and plans to add four more individuals to the team in Q3. The company is also adding professionals in key positions in other revenue-generating departments, including billing and reimbursement, genetic counseling and in the laboratory. CombiMatrix CEO Mark McDonough stated, ""Our sales force expansion provides us with greater opportunities to capitalize on the anticipated growth in the markets we serve. We expect to end 2015 with a sales organization that is nearly doubled in size compared to the beginning of the year,"
June 23, 2015
11:00 EDTVICLVical downgraded to Neutral from Buy at Roth Capital
Subscribe for More Information
09:14 EDTVICLOn The Fly: Pre-market Movers
Subscribe for More Information
June 22, 2015
19:00 EDTVICLOn The Fly: After Hours Movers
Subscribe for More Information
17:08 EDTVICLVical down 45% after herpes vaccine study fails to meet primary endpoint
Subscribe for More Information
16:12 EDTVICLVical reports top-line results from Phase 1/2 trial of genital herpes vaccine
Vical announced top-line results from an ongoing randomized, double-blind, placebo controlled Phase 1/2 clinical study of its therapeutic genital herpes vaccine, designed to reduce viral shedding and genital herpes lesions in herpes simplex virus type 2, or HSV-2, infected patients. The trial enrolled patients across seven U.S. sites and is evaluating two constructs: a monovalent, or gD, vaccine and a bivalent, or gD + UL46, vaccine, each formulated with Vical's proprietary Vaxfectin adjuvant. The top-line analysis compared pre-vaccination measurements for each arm with those taken during the swabbing period in months 2 and 3 following the last vaccine dose. Neither the monovalent nor bivalent vaccine met the primary endpoint. On prospectively defined secondary endpoints, the bivalent vaccine achieved statistically significant reductions in the rate of genital lesions and viral load from positive swabs versus baseline. Both the monovalent and bivalent vaccines were generally well tolerated. Safety data have been reviewed throughout the trial by an independent safety monitoring board, and no grade 4 adverse events or serious adverse events related to vaccination have been observed.
June 18, 2015
17:37 EDTBIOSBioScrip announces June 25 record date for rights offering
BioScrip set the record date for the previously disclosed upcoming rights offering as of the close of business June 25. The company expects the Rights Offering will commence no later than June 30 and conclude by the end of July 2015.
17:36 EDTIPCIIntellipharmaceutics receives new condtions for FDA approval of generic Focalin
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use